Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Chimeric Adenovirus(Ad5/35) Expressing Engineered Spike Protein Confers Immunity Against SARS-Cov-2 in Mice and Non-Human Primates

Seung-Phil Shin
ORCID logo ,
Kwang-Soo Shin
,
Jeong-Mi Lee
,
In-Kyung Jung
,
Jimo Koo
,
Seung-Woo Lee
,
Seowoo Park
,
Jieun Shin
,
Myunghwan Park
,
Bongju Park
,
Hanseul Oh
,
Bon-Sang Koo
,
JungJoo Hong
,
Choong-Min Ryu
ORCID logo ,
Jae-Ouk Kim
,
Taegwon Oh
,
Chang-Yuil Kang
*
Version 1 : Received: 7 April 2022 / Approved: 8 April 2022 / Online: 8 April 2022 (05:03:04 CEST)

A peer-reviewed article of this Preprint also exists.

Shin, S.-P.; Shin, K.-S.; Lee, J.-M.; Jung, I.-K.; Koo, J.; Lee, S.-W.; Park, S.; Shin, J.; Park, M.; Park, B.; Oh, H.; Koo, B.-S.; Hong, J.; Ryu, C.-M.; Kim, J.-O.; Oh, T.; Kang, C.-Y. The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines 2022, 10, 712. Shin, S.-P.; Shin, K.-S.; Lee, J.-M.; Jung, I.-K.; Koo, J.; Lee, S.-W.; Park, S.; Shin, J.; Park, M.; Park, B.; Oh, H.; Koo, B.-S.; Hong, J.; Ryu, C.-M.; Kim, J.-O.; Oh, T.; Kang, C.-Y. The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines 2022, 10, 712.

Abstract

Several COVID-19 platforms have been licensed across the world thus far, but vaccine platforms research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced Th1 immune response was specifically raised for the S protein, and these immune responses protected the NHP against live viruses. While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine.

Keywords

SARS-CoV-2; Variants; COVID-19 vaccine; Chimeric adenovirus-vectored vaccine; GS linker; Neutralizing activity; Th1 immune responses

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.